Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF28996 PK with Inhibitors and Antibiotics
NCT06277609Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Lu AF28996 in Parkinson's disease (PD) (2 arms), sponsored by Lundbeck. Primary endpoints: Maximum Observed Concentration and Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity. Started Feb 2024; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06277609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277609.